Skip to Content
cncpt-artikel_lb_atf

Updated data from CheckMate 9LA in advanced NSCLC show continuing benefit

Updated data from the CheckMate 9LA study shows that nivolumab plus ipilimumab with to cycles of chemotherapy gave a significant improvement of overall survival compared to chemotherapy alone in patients with non-small cell lung cancer (NSCLC). Data supports treatment with combinations in first line advanced NSCLC.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top